510(k) Report

510(k) · Cleared

Cleared

Fastpack Testo Immunoassay

K101388510(k) SpecialCleared Feb 18, 2011277-day reviewClass I21 CFR 862.1680

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Qualigen, Inc. · CDZ Radioimmunoassay, Testosterones And Dihydrotestosterone

Cleared on Feb 18, 2011 as substantially equivalent to K021972 (Qualigen, Inc., 2002) after a 277-day review. Its family tree reaches back 2 generations to 1997.

Decided
Feb 18, 2011
Review
277 days
Class
Class I
Product code
CDZ
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K964889 (1997). No later device cites it as a predicate yet.

  1. Root · 2 generations backK964889 Elecsys Testosterone AssayBoehringer Mannheim Corp. · 1997
  2. 1 generation backK021972 Fastpack Total Testosterone ImmunoassayQualigen, Inc. · 2002 · Recalled
  3. This deviceK101388 Fastpack Testo ImmunoassayQualigen, Inc. · 2011
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K964889Elecsys Testosterone AssayBoehringer Mannheim Corp.1997—
−1K021972Fastpack Total Testosterone ImmunoassayQualigen, Inc.20021
0 (this device)K101388Fastpack Testo ImmunoassayQualigen, Inc.2011—
FIG. 1 — Lineage of K101388, 1997–2011Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CDZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CDZ device

  1. #1 K252728 IDS-iSYS Total Testosteronescore 11.8 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K021972Fastpack Total Testosterone Immunoassay
Summary page 3
…Qualigen FastPack® Testo Qualigen FastPack® Testo Serum _________________ Immunoassay Serum or Plasma Only K021972 Intended Use for the in-vitro quantitative for the in-vitro quantitative…
Qualigen, Inc.20021

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 14 years and passes through 2 companies; a new generation was cleared every 8.5 years on median.
  • 1 of the 2 ancestors has a recall of any class.

How does its category compare?

All CDZ devices

CDZ Radioimmunoassay, Testosterones And Dihydrotestosterone: FDA decisions, review times, recalls and adverse event reports over 20 years. 2011, this device’s year, is highlighted.

FDA decisions per year · CDZ

2in 2024

2007: 12009: 12010: 22011: 22012: 12013: 12014: 12015: 22016: 42018: 12019: 42020: 12022: 12023: 12024: 22026 (partial year): 1
2007high 4 (2016) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CDZ

141in 2019

2016: 276 days median2019: 141 days median
2007high 276 (2016) · low 141 (2019)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · CDZ

1in 2025

2010: 12013: 12018: 12022: 12024: 12025: 12026 (partial year): 1
2007high 1 (2010) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · CDZ

17in 2025

2007: 62008: 32009: 12010: 12011: 192012: 92013: 72014: 102015: 72016: 52017: 122018: 52019: 32020: 122021: 72022: 32023: 102024: 112025: 17
2007high 19 (2011) · low 1 (2009)2025

MAUDE reports naming product code CDZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—06
20080—03
20091—01
20102—11
20112—019
20121—09
20131—17
20141—010
20152—07
2016427605
20170—012
20181—15
2019414103
20201—012
20210—07
20221—13
20231—010
20242—111
20250—117
20261—1—

What is it indicated for?

The FastPack® Testo, Immunoassay is a paramagnetic particle immunoassay for the in-vitro quantitative determination of total testosterone in human serum. or plasma. The FastPack® Testo Inmmnoassay is designed for use with the FastPack® System. It is intended strictly for in-vitro diagnostic use as an aid in the diagnosis and management of conditions involving excess or deficiency of this androgen.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K101388: Fastpack Testo Immunoassay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K101388

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026